Cerebral	cerebral	O	O	OTHERS	I
vasculitis	vasculitis	O	DISEASE	OTHERS	I
following	following	O	O	O	O
oral	oral	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
intake	intake	O	O	O	O
in	in	O	O	O	O
an	an	O	O	O	O
adult	adult	O	O	O	O
:	:	O	O	O	O
a	a	O	O	O	O
case	case	O	O	O	O
report	report	O	O	O	O
.	.	O	O	O	O

Methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
structurally	structurally	O	O	O	O
and	and	O	O	O	O
functionally	functionally	O	O	O	O
similar	similar	O	O	O	O
to	to	O	O	O	O
amphetamine	amphetamine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Cerebral	cerebral	O	O	OTHERS	I
vasculitis	vasculitis	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
amphetamine	amphetamine	CHEMICALS	O	OTHERS	I
abuse	abuse	O	O	OTHERS	I
is	is	O	O	O	O
well	well	O	O	O	O
documented	documented	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
in	in	O	O	O	O
rare	rare	O	O	O	O
cases	cases	O	O	O	O
ischaemic	ischaemic	O	O	OTHERS	I
stroke	stroke	O	DISEASE	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
after	after	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
intake	intake	O	O	O	O
in	in	O	O	O	O
children	children	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
the	the	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
63-year-old	63-year-old	O	O	O	O
female	female	O	O	O	O
who	who	O	O	O	O
was	was	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
hyperactivity	hyperactivity	O	DISEASE	OTHERS	I
and	and	O	O	O	O
suffered	suffered	O	O	O	O
from	from	O	O	O	O
multiple	multiple	O	O	O	O
ischaemic	ischaemic	O	O	OTHERS	I
strokes	strokes	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
consider	consider	O	O	O	O
drug-induced	drug-induced	O	O	O	O
cerebral	cerebral	O	O	OTHERS	I
vasculitis	vasculitis	O	DISEASE	OTHERS	I
as	as	O	O	O	O
the	the	O	O	O	O
most	most	O	O	O	O
likely	likely	O	O	O	O
cause	cause	O	O	O	O
of	of	O	O	O	O
recurrent	recurrent	O	O	O	O
ischaemic	ischaemic	O	O	OTHERS	I
strokes	strokes	O	DISEASE	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
absence	absence	O	O	O	O
of	of	O	O	O	O
any	any	O	O	O	O
pathological	pathological	O	O	O	O
findings	findings	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
diagnostic	diagnostic	O	O	O	O
work-up	work-up	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
conclude	conclude	O	O	O	O
that	that	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
mediated	mediated	O	O	O	O
vasculitis	vasculitis	O	DISEASE	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
considered	considered	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
neurological	neurological	O	O	OTHERS	I
symptoms	symptoms	O	O	OTHERS	I
and	and	O	O	O	O
a	a	O	O	O	O
history	history	O	O	O	O
of	of	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
potential	potential	O	O	O	O
side-effect	side-effect	O	O	O	O
,	,	O	O	O	O
though	though	O	O	O	O
very	very	O	O	O	O
rare	rare	O	O	O	O
,	,	O	O	O	O
represents	represents	O	O	O	O
one	one	O	O	O	O
more	more	O	O	O	O
reason	reason	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
very	very	O	O	O	O
restrictive	restrictive	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

